Interleukin-16 and vascular endothelial growth factor in the serum of bone tumor patients

The results of studies of interleukin 16 (IL-16) and vascular endothelial growth factor (VEGF) by ELIsa in the serum of patients with primary malignant tumors of bone and healthy age-matched to identify the possible correlation with the histological structure of the tumor and prognosis of the disease were presents. It is shown that the detection rate of IL-16 in serum in bone tumors was 93%, no significant differences in levels of IL-16 in considering the histological structure of tumor is not revealed. relationship between the size of the primary tumor and the content of IL-16 in serum were not found. overall 3- and 5-year survival of patients with malignant bone tumors content IL-16 in serum >33.0 pg/ml was significantly lower than patients with levels of IL-16 <33.0 pg/ml. osteosarcoma overall 5-year survival in patients with high IL-16 in serum was 1.6 times, with Ewing’s sarcoma in 1.7 times, chondrosarcoma – 1.8 times lower than in patients with the content IL-16 in serum <33.0 pg/ml. malignant bone tumors, VEGF levels were significantly higher than in borderline and benign tumors, statistical analysis of significant differences in the levels of VEGF in view of the morphological structure of the primary tumor has not revealed. maximum values VEGF marked with periosteal osteosarcoma, minimum – at paraosteal osteosarcoma – osteosarcoma with a favorable prognosis. when the content of IL-16 >33.0 pg/ml, which to our knowledge has been less favorable prognosis than patients with lower levels of IL-16, VEGF levels in the serum in all morphological variants of the structure of the primary tumor were higher than with IL-16 levels <33.0 pg/ml, but the differences were not statistically significant. In healthy people marked inverse relationship between the levels of VEGF and IL-16 in serum (r=–0.34), in benign tumors – a direct correlation (r=0.46), which is possible due to the peculiarities of the growth of the tumors. Initially high rates of IL-16 to meet the high values of VEGF in serum (p<0.05). Indicators of overall 3- and 5-year survival in patients with bone sarcomas levels of VEGF >493 pg/ml in serum were significantly lower than among those with low values of VEGF (<493 pg/ml; p<0.05). osteosarcoma no significant differences in the 3- and 5-year overall survival for baseline values of VEGF in blood serum. when Ewing sarcoma and chondrosarcoma of bone were significant differences in the 3- and 5-year overall survival, which depended on the baseline VEGF. Greatest figures 3 and 5-year overall survival observed in patients with bone sarcomas containing IL-16 <33 pg/ml VEGF <493 pg/ml and at least baseline IL-16 <33 pg/ml VEGF >493 pg/ml (p<0,05).

1. Лебедев К.А., Понякина И.Д. Иммунная недостаточность (выявление и лечение). М.: Медицинская книга, Н.Новгород: Издательство НГМА. 2003, 443 с.

2. Atanackovic D., Hildebrandt Y., Templin J. et al. Role of interleukin 16 in multiple myeloma. J. Natl. Cancer Inst. 2012, v. 104 (13), p. 1005-1020.

3. Baptista A.M., Camargo A.F., Filippi R.Z. et al. Correlation between the expression of vegf and survival in osteosarcoma. Acta. Ortop. Bras. 2014, v. 22 (5), p. 250-255.

4. Chen D., Zhang Y.J., Zhu K.W., Wang W.C. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. Tumour Biol. 2013, v. 34 (3), р. 1895-1899.

5. Compérat E., RouprêtM., DrouinS.J. et al. Tissue expression of IL-16 in prostate cancer and its association with recurrence after radical prostatectomy. Prostate. 2010, v. 70 (15), р. 1622-1627.

6. Dubois S.G., Shsterman S., Ingle A.M. et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children’s oncology group study. Clin. Cancer Res. 2011, v. 17, p. 5113-5122.

7. Fox E., Aplene R., Bagatell R. et al. A phase I trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor inhibitor, in children and adolescents with refractory solid tumors. J. Clin. Oncol. 2010, v. 28 (35), p. 5174-5181.

8. Gao L.B., Liang W.B., Xue H. et al. Genetic polymorphism of interleukin-16 and risk of nasopharyngeal carcinoma. Clin. Chim. Acta. 2009, v. 409 (1-2), p. 132-135.

9. Gao L.B., Rao L., Wang Y.Y. et al. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis. 2009, v. 2, No. 2, p. 295-299.

10. Glade Bender J.L., Lee A., Reid J.M. et al. Phase I pharmacokinetic and pharmacodynamics study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children’s oncology group Phase I consortium report. J. Clin. Oncol. 2013, v. 31 (24), p. 3034-3043.

11. Koike M., Sekigawa I., Okada M. et al. Relationship between CD4+/CD8+ T-cell ratio and T-cell activation in multiple myeloma: reference to IL-16. Leuk. Res. 2002, v. 26 (8), p. 705-711.

12. Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumor stage and previous therapy. Biomed. Pharmacother. 2001, v. 55 (2), p. 111-116.

13. Kushlinskii N.E., Timofeev Y.S., Solov’ev Y.N. et al. Components of the RANK/RANKL/OPG system, IL-6, IL8, IL-16, MMP-2, and calcitonin in the sera of patients with bone tumors. Bull. Exp. Biol. Med. 2014, v. 157 (4), p. 520-523.

14. Laberge S., Cruikshank W.W., Kornfeld H., Center D.M. Histamine-induced secretion of lymphocyte chemoattractant factor from CD8+ T-cells is independent of transcription and translation. Evidence for constitutive protein synthesis and storage. J. Immunol. 1995, v. 155 (6), p. 2902-2910.

15. Lammli J., Fan M., Rossenthal H.G. et al. Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma. Int. Orthop. 2012, v. 36 (11), p. 2307-2313.

16. Li S., Deng Y., Chen Z.P. et al. Genetic polymorphism of interleukin-16 influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population. Infect. Genet. Evol. 2011, v. 11 (8), p. 2083-2088.

17. Mahindra A., Anderson K.C. Role of interleukin 16 in multiple myeloma pathogenesis: a potential novel therapeutic target? J. Natl. Cancer Inst. 2012, v. 104 (13), p. 964-965.

18. Mathy N.L., Scheuer W., Lanzendörfer M. et al. Interleukin-16 stimulates the expression and production of proinflammatory cytokines by human monocytes. Immunology. 2000, v. 100 (1), p. 63-69.

19. Moon M.H., Jeong J.K., Seo J.S. et al. Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation. Exp. Mol. Med. 2011, v. 43 (3), p. 138-145.

20. Qu Y., Xu J., Jiang T. et al. Difference in pre- and post chemotherapy vascular endothelial growth factor levels as a prognostic indicator in osteosarcoma. J. Int. Med. Res. 2011, v. 39 (4), p. 1474-1482.

21. Rossi B., Schinzani G., Maccauro G. et al. Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis. BMC Musculoskelet. Disord. 2010, v. 11, p. 34.

22. Rumsaeng V., Cruikshank W.W., Foster B. et al. Human mast cells produce the CD4+ T-lymphocyte chemoattractant factor, IL-16. J. Immunol. 1997, v. 159 (6), p. 2904-2910.

23. Sharma V., Sparks J.L., Vail J.D. Human B-cell lines constitutively express and secrete interleukin-16. Immunology. 2000, v. 99 (2), p. 266-271.

24. Thomas G., Jacobs K.B., Yeager M. et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 2008, v. 40 (3), p. 310-315.

25. Van Cruijsen H., Voest E.E., Punt C.J. et al. Phase I evaluation of cediranib, a selective VEGFR signaling inhibitor, in combination with gefitinib in patients with advanced tumors. Eur. J. Cancer. 2010, v. 46, p. 901-911.

26. Versleijen-Jonkers Y.M., VlenterieM., van de LuijtgaardenA.C., van der Graaf W.T. Anti-angiogenic therapy, a new player in the field of sarcoma treatment. Crit. Rev. Oncol. Hematol. 2014, v. 91 (2), p. 172-185.

27. Yellapa A., Bahr J.M., Bitterman P. et al. Association of interleukin 16 with the development of ovarian tumor and tumor-associated neoangiogenesis in laying hen model of spontaneous ovarian cancer. Int. J. Gynecol. Cancer. 2012, v. 22 (2), p. 199-207.

28. Zhu J., Qin C., Yan F. et al. IL-16 polymorphism and risk of renal cell carcinoma: association in a Chinese population. Int. J. Urol. 2010, v. 17 (8), p. 700-707.

29. Zuang Y., Wei M. Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis. Tumor Biol. 2014, v. 35, p. 1745-1749.